Recombinant Hepatitis C Virus Core 2a protein (ab67726)

Overview

Description

  • NatureRecombinant
  • SourceEscherichia coli
  • Amino Acid Sequence
    • Amino acids2 to 119
    • TagsGST tag N-Terminus

Associated products

Specifications

Our Abpromise guarantee covers the use of ab67726 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Biological activityThis protein is immunoreactive with sera of HCV-infected individuals.
  • Applications

    Western blot

    ELISA

  • Purity> 95 % SDS-PAGE.
    Hepatitis C Virus Core 2a Core protein was purified by a proprietary chromatographic technique.
  • FormLiquid
  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

    Preservative: None
    Constituents: 50% Glycerol, 60mM Sodium chloride, 50mM Tris HCl, 10mM Glutathione, 0.25% sarkosyl, pH 8.0.

    This product is an active protein and may elicit a biological response in vivo, handle with caution.

General Info

  • Alternative names
    • Genome polyprotein
    • HCV 2a
    • HCV core 2a
    • HCV Core genotype 2a
    • HCV2a
    • Hepatitis C Virus Core genotype 2a
    see all
  • RelevanceHCV (Hepatitis C Virus) viral core protein forms the internal viral coat that encapsidates the genomic RNA and is enveloped in a host cell-derived lipid membrane. The hepatitis C virus (HCV) core protein represents the first 177 amino acids of the viral precursor polyprotein and is cotranslationally inserted into the membrane of the endoplasmic reticulum. The N terminus of the core protein is involved in transcriptional repression. There are over 20 different subtypes of Hepatitis C Virus; the preponderance and distribution of HCV genotypes varies globally. HCV Genotype information is important because of the role it plays in predicting HCV medical treatment response and treatment duration. Sustained cure rates (sustained viral response) of 75% or better occur in people with genotypes HCV 2 and 3 in 24 weeks of treatment. Genotypes 1a and 1b, the most prevalent worldwide, have the poorest rates of response to the present treatment regimen, which is a combination of pegylated alfa interferon 2b with ribavirin. HCV core protein is among the most conserved proteins in HCV and is known to induce sensitization of cytotoxic T lymphocytes (CTL). Therefore, it is a prime candidate for a component of a potential HCV vaccine.

References for Recombinant Hepatitis C Virus Core 2a protein (ab67726)

ab67726 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab67726.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"